Assessing the Effect of Decentralization of Laboratory Diagnosis for Drug-resistant Tuberculosis in Kenya
Published Date:Nov 2015
Source:Int J Tuberc Lung Dis. 19(11):1348-1353.
Pubmed Central ID:PMC5017007
Funding:CC999999/Intramural CDC HHS/United States
Drug susceptibility testing (DST) is recommended in Kenya to identify multidrug-resistant tuberculosis (MDR-TB) in persons registered for retreatment of tuberculosis (TB). DST is performed at a central laboratory with a two-step growth-based process and a regional laboratory with a simultaneous molecular- and growth-based process.
To compare proportions of retreatment cases that underwent DST and turnaround times for hospitals referring to the central versus regional laboratory.
Cases were persons registered for retreatment of TB during January 1, 2012 to December 31, 2013. Records were reviewed at 11 hospitals and 7 hospitals referring to the regional and central laboratories, respectively.
Overall, 238/432 (55%) and 88/355 (25%) of cases at hospitals referring to the regional and central laboratories, respectively, underwent DST. The mean time from case registration to receipt of DST results and initiation of MDR-TB treatment was faster for hospitals referring to the regional laboratory. Specimen transport, specimen testing, and receipt of DST results at hospitals were shorter for the regional laboratory (p < 0.05).
Testing was faster and more complete at hospitals referring to the regional laboratory. The low proportions of cases receiving DST warrant a comprehensive review of detection of MDR-TB in Kenya.
application/octet-stream image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg
You May Also Like: